Beta-adrenergic antagonists

Mechanism of Action - The Beta Blockade

• Competitive antagonists at β-adrenergic receptors, preventing binding of endogenous catecholamines (norepinephrine, epinephrine).
• Primarily targets β1 and/or β2 receptors, leading to a ↓ in intracellular signaling.

• Cardiac (β1): ↓ Heart rate (negative chronotropy), ↓ contractility (negative inotropy), and ↓ AV conduction velocity (negative dromotropy).
• Renal (β1): ↓ Renin release from juxtaglomerular cells.

⭐ Beta-blockers lower blood pressure not just by cardiac effects, but also by inhibiting β1 receptors on juxtaglomerular cells, which suppresses the entire Renin-Angiotensin-Aldosterone System (RAAS) cascade.

Classification & Agents - The Blocker Roster

• Non-selective (β1 & β2 Blockade)

  • Propranolol, Timolol, Nadolol, Pindolol
  • 📌 From N to Z (Nadolol → Propranolol)

• Cardioselective (β1 > β2 Blockade)

  • Atenolol, Betaxolol, Esmolol, Acebutolol, Metoprolol
  • 📌 From A to M (Acebutolol → Metoprolol)
  • Safer for patients with reactive airway disease.

• Combined α & β Blockade

  • Carvedilol & Labetalol
  • Useful in heart failure (Carvedilol) and hypertensive emergencies (Labetalol).

• Partial Agonists (Intrinsic Sympathomimetic Activity - ISA)

  • Pindolol, Acebutolol
  • Less bradycardia; not for post-MI or heart failure.

⭐ Esmolol is a very short-acting β1-selective blocker. Its t½ of ~9 min makes it ideal for IV use in surgical settings or acute arrhythmias to allow for rapid titration.

Therapeutic Uses - The Clinical Playbook

• Cardiovascular System:

  • Hypertension: Especially with compelling indications (e.g., post-MI, stable HFrEF).
  • Ischemic Heart Disease: ↓ Myocardial O₂ demand in stable angina; ↓ mortality post-MI.
  • Heart Failure (HFrEF): ↓ Mortality in stable, chronic failure. (📌 Bisoprolol, Carvedilol, Metoprolol succinate).
  • Tachyarrhythmias: Rate control in atrial fibrillation/flutter; SVT management.

• Other Key Applications:

  • Hyperthyroidism: Symptomatic relief (palpitations, tremor).
  • Glaucoma: Topical agents (e.g., Timolol) ↓ aqueous humor production.
  • Neurologic: Migraine prophylaxis, essential tremor, performance anxiety.
  • Portal Hypertension: Prophylaxis for variceal bleeding (non-selective agents).

⭐ In chronic systolic heart failure, specific beta-blockers (carvedilol, metoprolol succinate, bisoprolol) are proven to reduce mortality by protecting the heart from chronic sympathetic overstimulation.

Adverse Effects & Cautions - The 'B' Ware List

📌 B's of Beta-Blocker AEs:

• Bradycardia & AV Block: Contraindicated in high-degree AV block (2nd/3rd).
• Bronchoconstriction: Non-selective agents can trigger asthma/COPD exacerbations.
• Bad for Acute Decompensated HF: Negative inotropy worsens acute overload.
• Blood Glucose Masking: Masks adrenergic hypoglycemia symptoms (tachycardia, tremor).
• Blue Extremities/Fatigue: ↓CO causes cold extremities, exercise intolerance.
• CNS effects (sedation, depression), erectile dysfunction.

⚠️ Abrupt Cessation: Risk of rebound HTN, tachycardia, angina from receptor upregulation.

⭐ Beta-blockers mask adrenergic hypoglycemia symptoms (tachycardia, tremors), but sweating (cholinergic) persists, serving as a crucial warning sign in diabetic patients.

High-Yield Points - ⚡ Biggest Takeaways

• Beta-blockers competitively antagonize β-adrenergic receptors, decreasing heart rate, contractility, and blood pressure.
• Cardioselective (β1) agents like metoprolol and atenolol are preferred in patients with asthma or COPD.
• Non-selective agents (e.g., propranolol) can cause bronchoconstriction by blocking β2 receptors.
• Key uses include ischemic heart disease, stable heart failure, hypertension, and rate control.
• Adverse effects include bradycardia, fatigue, and masking symptoms of hypoglycemia.
• Avoid abrupt withdrawal to prevent rebound hypertension and tachycardia.